Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 5, 2014, Pages 1155-1165

  Romanowski, Barbara ^a   Schwarz, Tino F ^b   Ferguson, Linda M ^c   Ferguson, Murdo ^c   Peters, Klaus ^d   Dionne, Marc ^e   Schulze, Karin ^f   Ramjattan, Brian ^g   Hillemanns, Peter ^h   Behre, Ulrich ⁱ   Suryakiran, Pemmaraju ^j   Thomas, Florence ^k   Struyf, Frank ^k  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Department of Family Medicine and Emergency Medicine   (Canada)

^d Centre Hospitalier Universitaire ^*  (Germany)

^e LAVAL UNIVERSITY   (Canada)

^f Medizinische Hochschule Hannover ^*  (Germany)

^g First Line Medical Services Ltd   (Canada)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ NONE   (Germany)

^j GlaxoSmithKline Pharmaceuticals Ltd   (India)

^k GSK   (Belgium)

more..

Author keywords

Administration schedule; Female adolescents; Human papillomavirus vaccine; Immunogenicity; Randomized controlled trial; Safety; Women

Indexed keywords

WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CHILD; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; NORMAL HUMAN; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; VACCINATION; YOUNG ADULT; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; IMMUNOLOGY; TIME; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CHILD; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNITY, CELLULAR; PAPILLOMAVIRUS VACCINES; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84901396246     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28022     Document Type: Article

References (35)

1. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09) 61248-4
2. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx.doi.org/10.1016/S1470-2045(11) 70286-8
3. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al.; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65; PMID:15541448; http://dx.doi.org/ 10.1016/S0140-6736(04)17398-4
4. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, et al.; GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85; PMID:19962185; http://dx.doi.org/10.1016/S0140-6736(09)61567-1
5. Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26:6630-8; PMID:18845199; http://dx.doi.org/10.1016/j.vaccine.2008.09.049
6. Angelo M-G, David M-P, Zima J, Baril L, Dubin G, Arellano F, Struyf F. Pooled analysis of large and long-term safety data from the human papilloma-virus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014; (Forthcoming); PMID:24644063; http://dx.doi.org/10.1002/pds.3554
7. Garçon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 2011; 25:217-26; PMID:21815697; http://dx.doi.org/10. 2165/11591760-000000000-00000
8. Goldie SJ, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008; 16:86-96; PMID:19027626; http://dx.doi.org/10.1016/S0968-8080(08)32409-4
9. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, et al.; CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-51; PMID:21908768; http://dx.doi.org/10.1093/jnci/djr319
10. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, et al.; HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71; PMID:17531764; http://dx.doi.org/10. 1016/j.jadohealth.2007.02.015
11. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7:1374-86; PMID:22048171; http://dx.doi.org/10.4161/hv. 7.12.18322
12. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsagué X, et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5
13. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet SM, Catteau G, Thomas F, Descamps D. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin 2011; 7:958-65; PMID:21892005; http://dx.doi.org/10.4161/hv.7.9.15999
14. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24(Suppl 3):S106-13; PMID:16949996; http://dx.doi.org/10.1016/j.vaccine.2006.05.110
15. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34; PMID:18948732; http://dx.doi.org/10.4161/hv.4.6.6912
16. Schwarz TF, Kocken M, Petäjä T, Einstein MH, Spaczynski M, Louwers JA, Pedersen C, Levin M, Zahaf T, Poncelet S, et al. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin 2010; 6:1054-61; PMID:21157180; http://dx.doi.org/10.4161/hv.6.12.13399
17. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8:390-7; PMID:22327492; http://dx.doi.org/10.4161/hv.18865
18. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al.; HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705-19; PMID:19684472; http://dx.doi.org/10.4161/hv.5.10. 9518
19. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al.; HPV-010 Study Group. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7:1343-58; PMID:22048173; http://dx.doi.org/10.4161/hv.7.12.18281
20. Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, Lockman L, Giannini S, Deschamps M. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin 2010; 6:407-19; PMID:20953154; http://dx.doi.org/10.4161/hv.6.5.11023
21. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008; 26:6244-57; PMID:18694795; http://dx.doi.org/10.1016/j. vaccine.2008.07.056
22. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, et al.; CVT Group. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013; 6:1242-50; PMID:24189371; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0203
23. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, et al.; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx.doi.org/10.1016/ S1470-2045(11)70287-X
24. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131:2349-59; PMID:22323075; http://dx.doi.org/10.1002/ijc.27485
25. Naud P, Roteli-Martins CM, De Carvalho N, Teixeira J, Borba P, Sanchez N, Zahaf T, Geeraerts B, Descamps D. HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years. Abstract presented at 27th International Papillomavirus Conference and Clinical Workshop, Berlin, Germany; September 17-22, 2011 [Internet]. Applied/Clinical Science Abstract Book; p.153 [cited 2013 Nov 4]. Available from: http://www.hpv2011.org/pics/1/4/ Abstract%20Book%202%20APSC%20WEBB%20110922.pdf
26. Moscicki AB, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine 2012; 31:234-41; PMID:23063422; http://dx.doi.org/10.1016/ j.vaccine.2012.09.037
27. Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. J Infect Dis 2013; 207:1753-63; PMID:23242542; http://dx.doi.org/10.1093/infdis/jis619
28. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Hervé C, Descamps D. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013; 31:5745-53; PMID:24091311; http://dx.doi.org/10.1016/j.vaccine.2013.09.032
29. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802; PMID:23632723; http://dx.doi.org/10. 1001/jama.2013.1625
30. Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES 3rd, Kollmann TR. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30:3572-9; PMID:22469863; http://dx.doi.org/10.1016/ j.vaccine.2012.03.051
31. Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis 2013; 208:1325-34; PMID:23901077; http://dx.doi.org/10.1093/infdis/jit363
32. Taylor LD, Hariri S, Sternberg M, Dunne EF, Markowitz LE. Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008. Prev Med 2011; 52:398-400; PMID:21108962; http://dx.doi.org/10.1016/j.ypmed.2010.11.006
33. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries - an update. Stockholm: ECDC; 2012 [Internet]; p.6 [cited 2013 Nov 4]. Available from: http://ecdc.europa.eu/en/publications/ Publications/20120905-GUI-HPV-vaccine-update.pdf.
34. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep 2013; 62:591-5; PMID:23884346
35. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, et al.; HPV-010 Study Group. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359-73; PMID:22048172; http://dx.doi.org/10.4161/hv.7.12.18282